Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics.
Manifold Bio expands its leadership team to support scaling its AI and in vivo targeted-biologics platform. The announcement provides no further details about the team expansion.
Roche pays Manifold Bio $55 million upfront in a research deal focused on developing better brain shuttles. The deal draws on Manifold's technology as Roche searches for additional ways to deliver medicines to the brain, the focus of the research agreement.
Roche gains access to Manifold Bio’s drug-discovery technology in a $55 million deal to develop shuttles that move medicines across the blood-brain barrier.
Manifold Bio partners with Roche to develop medicines for neurological diseases using AI-driven technology. The collaboration centers on neurological-disease research and development. The agreement includes an upfront payment and potential revenue, while the available report does not state their amounts.
